Biotech Updates

GM Tomato Enriched with L-DOPA Offers Affordable Medicine for Parkinson's Disease

December 16, 2020

Scientists led by a team from John Innes Centre (JIC) have developed a genetically modified (GM) tomato enriched with the Parkinson's disease drug L-DOPA in what could become a new, affordable source of one of the world's essential medicines.

L-DOPA is produced from tyrosine, an amino acid found in many food products. The research team inserted a gene encoding a tyrosinase, an enzyme that uses tyrosine to build molecules such as L-DOPA. This elevated the level of L-DOPA specifically in the fruit part of the plant and led to higher yields than those associated with L-DOPA production in the whole plant.

Tomato was chosen as a widely cultivated crop for scaled-up production and potentially offering a standardized and controlled natural source of L-DOPA. The John Innes Centre led team modified the tomato fruit by introducing a gene responsible for the synthesis of L-DOPA in beetroot where it functions in the production of the pigments betalains. The levels achieved in the tomato fruit, 150mg of L-DOPA per kg of tomatoes, were comparable to those observed in other L-DOPA accumulating plants, without any of the known drawbacks that have hampered plant metabolic production of the drug previously.

Parkinson's disease is a growing problem in developing countries where many people cannot afford the daily $2 price of synthetic L-DOPA . Also known as Levodopa, L-DOPA has been the gold standard therapy for Parkinson's disease since its establishment as a drug in 1967. It is one of the essential medicines declared by the World Health Organisation (WHO).

For more details, read the press release on the JIC website.

You might also like: